http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020325131-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9d005e60ac56918418b68a68ef84535 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d86fcd3b878a5d6b225ca4ee355e7e37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3662f68059594bc4cedf983a7343273 |
| publicationDate | 2020-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020325131-A1 |
| titleOfInvention | Novel crystalline salt forms of 3-(1,2,4-triazolo[4,3-a]pyridine-3-ylethynyl)-4-methyl-n-(4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl)benzamide for medical application |
| abstract | The invention relates to the organic chemistry, pharmacology and medicine, and concerns the prevention and treatment of human and animal diseases associated with the disruption of the activity of various kinases, in particular Abl kinase, for example diseases such as leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, breast cancer, non-small cell lung cancer, gastrointestinal stromal tumors, ovarian cancer, lymphoma, using a new salt form of 3-(1,2,4-triazolo[4,3-a]pyridine-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl)benzamide. The salt of this compound with methanesulfonic acid, n n n n n n n n n n or its hydrate, solvate, as well as polymorphic modifications that have the ability to inhibit the activity of kinases, in particular Abl kinases. The present invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of a salt of the invention, to a method for preparing a crystalline salt of the invention, as well as to a method for treating oncological diseases in a subject. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112505131-A |
| priorityDate | 2016-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 317.